Crohn-betegség: vizsgálatok itt: Kína

In Kína 73 Also abroad 422

73 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Beijing, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei, Huaian, Huizhou, Kunming, Nanjing, Shanghai, Shaoguan, Shenzhen, Shijiazhuang, Shiyan, Suining, Taizhou, Wuhan, Wuxi, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhenjiang
Életkor
16 év to 80 év
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
2. fázisTaking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen, Zhenjiang
Életkor
18 év to 80 év
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
2. fázisTaking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen, Zhenjiang
Életkor
18 év to 80 év
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
3. fázisTaking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
Életkor
3 év to 64 év
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
2/3. fázisTaking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Huizhou, Jinhua, Lanzhou, Luoyang, Luzhou, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Shenzhen, Suzhou, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhuzhou, Zunyi
Életkor
18 év and over
People
1092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
4. fázisTaking people
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Where
Guangzhou, Hangzhou, Hefei, Shanghai
Életkor
18 év and over
People
78
Run by
Xian-Janssen Pharmaceutical Ltd.
See details and how to joinNCT07310095
3. fázisTaking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Changzhou, Chongqing, Fuzhou, Guangzhou, Nanjing, Wuhan
Életkor
18 év and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
3. fázisTaking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Hefei, Huai'an, Lanzhou, Nanjing, Ningbo, Shanghai, Wenzhou, Wuhan, Wuxi, Xiamen, Zhuzhou
Életkor
18 év and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
3. fázisTaking people
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Where
Beijing, Changsha, Changzhou, Foshan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Huizhou, Kunming, Lanzhou, Nanchang, Nanjing, Nanyang, Ningbo, Qingyuan, Quzhou, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wenzhou, Wuhan, Wuhu, Xuzhou, Yancheng, Yantai, Yinchuan, Zhenjiang, Zhuhai
Életkor
18 év to 80 év
People
408
Run by
Takeda
See details and how to joinNCT05837897
2. fázisTaking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang, Suzhou, Wuhan, Xiamen, Zhejiang
Életkor
18 év to 75 év
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
2. fázisTaking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
Életkor
18 év to 75 év
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Chengdu, Ganzhou, Guangzhou, Haikou, Huai'an, Huizhou, Jinhua, Kunming, Nanchang, Shanghai, Shenyang, Shijiazhuang, Suzhou, Xiamen, Xi'an, Zhenjiang
Életkor
16 év to 80 év
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
3. fázisTaking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changshu, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Jinan, Jingzhou, Jinhua, Luzhou, Mianyang, Nanjing, Qingdao, Qingyuan, Shanghai, Shenzhen, Suzhou, Taizhou, Wenzhou, Wuhan, Wuxi, Xiamen, Yangzhou
Életkor
16 év to 80 év
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
3. fázisTaking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Guangzhou, Huizhou, Shanghai, Wuxi
Életkor
16 év to 80 év
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Zhengzhou
Életkor
2 év to 17 év
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Nanchang, Nanning, Ningbo, Shanghai, Shenzhen, Taizhou, Wuhan, Wuxi, Xiamen, Zhengzhou, Zhuzhou
Életkor
16 év to 80 év
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
4. fázisTaking people
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Where
Beijing
Életkor
6 év to 17 év
People
30
Run by
Taizhou Mabtech Pharmaceutical Co.,Ltd
See details and how to joinNCT05906576
1. fázisTaking people
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
Where
Hangzhou
Életkor
18 év to 55 év
People
88
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07758101
4. fázisTaking people
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
Where
Fuyang, Huaian, Meihekou, Shanghai, Yancheng, Zhengzhou, Zhoukou
Életkor
18 év to 70 év
People
50
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07663526
No phaseTaking people
Endoscopic Stricturotomy Versus Balloon Dilation for Small Bowel Fibrotic Strictures in Crohn's Disease
Where
Guangzhou
Életkor
18 év to 70 év
People
244
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07833332
No phaseTaking people
Prediction of Postoperative Recurrence in Crohn's Disease
Where
Guangzhou
Életkor
18 év to 70 év
People
250
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07824791
4. fázisTaking people
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Where
Guangzhou
Életkor
6 év to 17 év
People
30
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07564505
No phaseTaking people
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease
Where
Guangzhou
Életkor
18 év and over
People
300
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07504510
No phaseTaking people
Fecal Microbiota Transplantation in Pediatric Crohn's Disease
Where
Wuhan
Életkor
2 év to 16 év
People
40
Run by
Biao Zou
See details and how to joinNCT05321745
No phaseTaking people
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Where
Wuhan
Életkor
2 év to 16 év
People
50
Run by
Tongji Hospital
See details and how to joinNCT05321758